GMP – Page 55 – Pharma.Tips

PQ dossier deficiency during variation management – PQ assessment risk and mitigation

Mitigating Deficiencies in PQ Dossier During Variation Management Managing variations within the pharmaceutical manufacturing space is fraught with challenges, particularly when it comes to maintaining compliance with Prequalification (PQ) requirements…

API change not reported during requalification – documentation gaps reviewers flag

Addressing API Changes Not Reported During Requalification: A Practical Playbook In the pharmaceutical manufacturing landscape, the consequences of undocumented Active Pharmaceutical Ingredient (API) changes during requalification processes can be significant.…

Equipment downtime due to cleaning during equipment changeover – inspection-ready cleaning optimization

Optimizing Equipment Cleaning to Minimize Downtime During Changeover Downtimes during changeovers, primarily attributed to cleaning processes, are a persistent challenge in pharmaceutical manufacturing. These downtimes not only disrupt production schedules…

API change not reported during dossier submission – preventing PQ suspension

Managing Unreported API Changes During Dossier Submission to Prevent PQ Suspension In the dynamic landscape of pharmaceutical manufacturing and regulatory compliance, the failure to report Active Pharmaceutical Ingredient (API) changes…

Documentation not aligned to WHO during API sourcing – CAPA aligned to WHO standards

Aligning API Sourcing Documentation with WHO Standards: A Practical Guide In the pharmaceutical industry, ensuring the alignment of documentation with WHO standards during Active Pharmaceutical Ingredient (API) sourcing is crucial…

Supplier WHO GMP non-compliance during API sourcing – WHO inspector expectations explained

Understanding WHO GMP Non-Compliance During API Sourcing: A Practical Playbook Supplier WHO GMP non-compliance during API sourcing poses significant risks to pharmaceutical manufacturers, potentially leading to serious regulatory repercussions and…

Inefficient CIP cycle during CPV review – validated efficiency improvement

Addressing an Inefficient CIP Cycle During CPV Review for Enhanced Manufacturing Performance In pharmaceutical manufacturing, the efficiency of Cleaning in Place (CIP) cycles significantly impacts overall yield and compliance with…

API site WHO GMP risk during prequalification preparation – evidence pack for WHO audits

Managing WHO GMP Risks During API Site Prequalification Preparation As pharmaceutical professionals navigate the regulatory landscape for prequalification, ensuring compliance with WHO GMP standards is a daunting but critical task.…

Inadequate WHO GMP training during remediation planning – gap remediation roadmap

Comprehensive Guide for Addressing Inadequate WHO GMP Training in Remediation Planning In the fast-paced world of pharmaceutical manufacturing, inadequate WHO GMP training during remediation planning can significantly hinder compliance efforts.…

Inconsistent alignment with WHO TRS during API sourcing – gap remediation roadmap

Strategies for Bridging Gaps in API Sourcing Alignment with WHO TRS Inconsistent alignment with WHO TRS during API sourcing can lead to quality discrepancies, regulatory failures, and potential disruptions in…

Ineffective cleaning validation scope during validation lifecycle – cycle time reduction with compliance assurance

Addressing Ineffective Cleaning Validation Scope During the Validation Lifecycle Cleansing validation is a critical aspect of pharmaceutical manufacturing that ensures product safety and compliance with regulatory standards. However, ineffective cleaning…

WHO GMP gap identified during WHO inspection – evidence pack for WHO audits

“`html Addressing WHO GMP Gaps Identified in Inspections: An Actionable Playbook In the dynamic landscape of pharmaceutical manufacturing, identifying and addressing gaps in Good Manufacturing Practice (GMP) compliance is crucial…